How long does 4-FMA last?

The total duration of 4-FMA via oral is 4 hours to 8 hours. Onset typically occurs within 20 minutes to 40 minutes. Peak effects last 2 hours to 5 hours.

4-FMA — SubstanceWiki

4-FMA

Substituted amphetamines · Entactogen, Stimulants

9 dangerous interactions — combining 4-FMA with certain substances may be life-threatening.

See all

Entactogen, Stimulants(Substituted amphetamines)

Quick Dosage

oral50–75 mg (common)

Total duration (oral)4hr–8hr

View full details

4-Fluoromethamphetamine (4-FMA) is a fluorinated analog of methamphetamine in which a fluorine atom occupies the 4-position (para) of the phenyl ring. As the N-methyl homolog of 4-FA, it is classified as both an Entactogen and Stimulant, with a dual pharmacological profile combining methamphetamine's potent catecholaminergic stimulation with meaningful serotonergic (empathogenic) activity. The para-fluorine substitution, consistent with the 4-FA series, produces significant serotonin releasing activity compared to 2-FMA or 3-FMA.

Community reports describe 4-FMA as producing effects analogous to a more potent version of 4-FA — the combination of strong focused stimulation and emotional warmth — with greater intensity than 4-FA and a longer duration attributable to the N-methyl group enhancing CNS penetrance and extending the half-life. The Reddit thread "Who else has been researching 4-FMA?" reflects community engagement with this compound, though the body of user experience is smaller than for 4-FA.

4-FMA shares the cardiovascular hazards and neurotoxicity concerns of 4-FA, amplified by the higher potency and longer duration that come with N-methylation. The Dutch epidemiological experience with 4-FA — documenting hypertensive crises and deaths, particularly with alcohol co-administration — is directly relevant to 4-FMA, which likely carries comparable or greater risk per milligram. This is a compound that demands particular caution and is not recommended for inexperienced users.

How It Feels

The onset of 4-FMA arrives within thirty to fifty minutes as a converging current of stimulation and emotional warmth. Energy builds in the body while a gentle expansion of empathy opens in the chest. The heart rate climbs, a light flush rises in the face, and there is a growing sense that the coming hours hold the potential for both productivity and genuine connection. The dual onset is smoother and more evenly blended than 4-FA, without the distinct two-phase progression.

As the effects build, 4-FMA occupies a middle position between functional stimulant and social empathogen. Focus is enhanced but not rigid; there is enough cognitive sharpness to hold complex conversations or manage tasks, but also enough emotional warmth to make those conversations genuinely engaging. Sociability increases, and there is a moderate empathogenic quality: openness, affection, and reduced social anxiety that make group settings feel comfortable and inviting. Music is enriched but not transformed. Touch sensitivity is mildly increased. The body buzzes with a contained energy, warm and light, with the usual stimulant markers of jaw tension, mild sweating, and appetite suppression.

At the peak, roughly two to three hours in, the blend of stimulation and empathy holds steady. The euphoria is present but moderate, less dramatic than 4-FA and certainly less than MDMA, but persistent and pleasant. The stimulant component prevents the dreamy passivity that can accompany more serotonergic substances, keeping the mind agile and the body active. Heart rate is elevated, body temperature runs slightly high, and the jaw clenches with quiet persistence. The experience has a versatile quality, suitable for dancing, working, socializing, or any combination thereof.

The offset is gradual, stretching over four to six hours as the combined effects slowly taper. The empathogenic warmth fades first, leaving clean stimulation that eventually gives way to a mild fatigue. The comedown is moderate: less depleting than strongly serotonergic compounds but more noticeable than purely dopaminergic stimulants. There may be some emotional flatness the following day, a quiet reflection of serotonin expenditure. Sleep is delayed but achievable, and recovery is typically complete within a day.

Detection Methods

Standard Drug Panel Inclusion

4-FMA (4-Fluoromethamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.

Urine Detection

Due to the structural similarity to amphetamine, 4-FMA (4-Fluoromethamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 4-FMA (4-Fluoromethamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 4-FMA (4-Fluoromethamphetamine) unless the specific assay has unusually broad cross-reactivity.

Blood and Saliva Detection

4-FMA (4-Fluoromethamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.

Hair Follicle Detection

Hair follicle analysis can theoretically detect 4-FMA (4-Fluoromethamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 4-FMA (4-Fluoromethamphetamine).

Confirmatory Testing

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 4-FMA (4-Fluoromethamphetamine). These techniques can distinguish 4-FMA (4-Fluoromethamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 4-FMA (4-Fluoromethamphetamine) must be available to the testing laboratory for positive identification.

Reagent Testing

Marquis reagent produces no reaction or a faint orange-brown color with 4-FMA (4-Fluoromethamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 4-FMA (4-Fluoromethamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.

Interactions

Substance	Status	Note
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
25x-NBOMe	Unsafe	—
2C-T-x	Unsafe	—
DOx	Unsafe	—
PCP	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—
Caffeine	Uncertain	—
Cannabis	Uncertain	—
Cocaine	Uncertain	—
GHB	Uncertain	—
Ketamine	Uncertain	—

Showing 69 key interactions out of 72 total.

Toxicity & Safety

Cardiovascular Risk

4-FMA's most serious risk is cardiovascular, directly extrapolating from 4-FA's documented adverse event profile. The triple releasing mechanism — particularly the combination of serotonin, dopamine, and norepinephrine release — creates conditions for acute hypertension, and the additional potency from N-methylation makes this risk more significant per milligram than 4-FA.

Neurotoxicity

Para-substituted fluoromethamphetamines are expected to carry serotonergic neurotoxicity risk. Animal studies on the fluoroamphetamine series have documented serotonin axon terminal damage, and the N-methyl group increases the compound's ability to cross the blood-brain barrier, potentially amplifying neurotoxic exposure at any given peripheral dose.

Alcohol Interaction Risk

The 4-FA Dutch case experience established that alcohol dramatically amplifies the cardiovascular risk of para-fluoroamphetamines. This risk is fully applicable to 4-FMA and should be treated as an absolute contraindication for co-administration.

Duration and Sleep Disruption

The 6–10 hour duration means sleep disruption is very likely unless dosing is carefully timed. Combined with sympathomimetic cardiovascular activation, extended sleeplessness contributes cumulative physiological stress.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

LD50 (mouse; i.p.) of 4-FMA is unknown. While 4-FA does not cause long-lasting depletion of brain serotonin unlike MDMA or 4-FA's analogs 4-CA and 4-BA, it is unknown whether this also applies to 4-FMA as well.

4-FMA is reported to be particularly caustic in comparison to other compounds and can, therefore, cause chemical burns within the nasal passage and throat if it is insufflated.

It is strongly recommended that one use harm reduction practices when using this substance.

As with other stimulants, the chronic use of 4-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 4-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). This is how long it takes to reduce the tolerance for the stimulating effects. Tolerance for the entactogenic effects may take a longer period to reduce. 4-FA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 4-FMA all stimulants will have a reduced effect.

Psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. T

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 2 weeks

4-FMA

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(4)

Cognitive & Perceptual Effects

Cognitive(3)

Pharmacology

Mechanism of Action

Receptor Profile

Pharmacokinetics

Potency Considerations

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Development

Community Research

Post-Netherlands Regulatory Context

Harm Reduction

Dose Significantly Lower than 4-FA

Absolute Contraindication with Alcohol

Treat as More Potent 4-FA

Drug Testing

Recovery Intervals

Toxicity & Safety

Cardiovascular Risk

Neurotoxicity

Alcohol Interaction Risk

Duration and Sleep Disruption

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (7)

Community Discussions (1)

See Also

References (4)

Frequently Asked Questions